Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans
- PMID: 8851621
- PMCID: PMC163208
- DOI: 10.1128/AAC.40.3.812
Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans
Abstract
Penetration of ceftriaxone into heart tissues (valves, myocardium, auricles, and pericardium) and mediastinal tissues (fat and sternal bone) was evaluated after two regimens of ceftriaxone administration. Ten patients (group 1) were given 1,000 mg of ceftriaxone intravenously 30 min before anesthesia. Ten other patients (group 2) received the same dose and then a second 1,000-mg dose at the time of initiation of cardiopulmonary bypass. Similar and very satisfactory penetrations of ceftriaxone into tissue were observed for both groups. During opening and closure of the thorax, mean ceftriaxone concentration was in excess of the MIC at which 90% of the potential pathogens were inhibited (> or = 4 micrograms/g) in the thoracic fat, the sternal bone, and the pericardium. No significant differences between the two administration regimens in penetration of ceftriaxone into tissue were observed. During cardiopulmonary bypass, the ceftriaxone concentration was > or = 4 micrograms/g in the myocardium, the endocardium, and the auricle. The regimen of ceftriaxone administration did not significantly influence penetration of the drug into heart tissues. However, for some patients in the two groups and mainly in the sternal bone at the time of thorax closure (6 patients in group 1 and 5 patients in group 2), ceftriaxone levels in tissues were less than the MICs (4 micrograms/g) for some potential pathogens (methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis). During the different steps of the surgical procedures, all (10 of 10) patients in each group had tissue ceftriaxone levels greater than the MICs for gram-negative aerobic bacilli (0.1 microgram/g), except for Pseudomonas spp.
Similar articles
-
[Penetration of ceftriaxone (1 or 2 gr intravenous) into mediastinal and cardiac tissues in man].Pathol Biol (Paris). 1995 Apr;43(4):364-9. Pathol Biol (Paris). 1995. PMID: 7567130 Clinical Trial. French.
-
Penetration of vancomycin into mediastinal and cardiac tissues in humans.Antimicrob Agents Chemother. 1994 Feb;38(2):396-9. doi: 10.1128/AAC.38.2.396. Antimicrob Agents Chemother. 1994. PMID: 8192475 Free PMC article. Clinical Trial.
-
[Penetration of vancomycin in cardiac and mediastinal tissues in humans].Pathol Biol (Paris). 1994 May;42(5):520-4. Pathol Biol (Paris). 1994. PMID: 7824325 Clinical Trial. French.
-
Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.Clin Pharmacokinet. 2001;40(9):685-94. doi: 10.2165/00003088-200140090-00004. Clin Pharmacokinet. 2001. PMID: 11605716 Review.
-
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.Drugs. 2002;62(7):1041-89. doi: 10.2165/00003495-200262070-00005. Drugs. 2002. PMID: 11985490 Review.
Cited by
-
An antibiotic loaded ceramic sternum to treat destroyed infected sternum: 4 cases.J Thorac Dis. 2020 Mar;12(3):209-216. doi: 10.21037/jtd.2020.01.70. J Thorac Dis. 2020. PMID: 32274086 Free PMC article.
-
An Aminoglycoside-Sparing Regimen with Double Beta-Lactam to Successfully Treat Granulicatella adiacens Prosthetic Aortic Valve Endocarditis-Time to Change Paradigm?Infect Dis Rep. 2024 Mar 14;16(2):249-259. doi: 10.3390/idr16020020. Infect Dis Rep. 2024. PMID: 38525767 Free PMC article.
-
Ampicillin and Ceftobiprole Combination for the Treatment of Enterococcus faecalis Invasive Infections: "The Times They Are A-Changin".Antibiotics (Basel). 2023 May 9;12(5):879. doi: 10.3390/antibiotics12050879. Antibiotics (Basel). 2023. PMID: 37237782 Free PMC article.
-
Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.Clin Pharmacokinet. 2009;48(2):89-124. doi: 10.2165/00003088-200948020-00002. Clin Pharmacokinet. 2009. PMID: 19271782 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous